샘플 요청 목록

 카트 문의
시장보고서
상품코드
2132248

맞춤형 진단 시장 규모, 점유율, 동향 분석 보고서 : 검사 유형별, 기술별, 용도별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

Personalized Diagnostics Market Size, Share & Trends Analysis Report By Testing Type, By Technology, By Application, By End-use, By Region, And Segment Forecasts, 2026 - 2033
발행일: | 리서치사: 구분자 Grand View Research | 페이지 정보: 영문 150 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




가격
Unprintable PDF & Excel (Single User License) help
보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.
US $ 5,950 금액 안내 화살표 ￦ 8,074,000
Printable PDF & Excel (5-User License) help
보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.
US $ 6,950 금액 안내 화살표 ￦ 9,431,000
Printable PDF & Excel (Enterprise License) help
PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.
US $ 8,950 금액 안내 화살표 ￦ 12,145,000
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

맞춤형 진단 시장 요약

세계의 맞춤형 진단 시장 규모는 2025년에 121억 달러로 평가되며, 2026년 134억 달러에서 2033년까지 300억 달러로 성장할 것으로 예상되며, 2026년부터 2033년까지 CAGR은 12.2%에 달할 것으로 예측됩니다.

2025년에는 북미가 시장을 주도하며 매출 점유율의 39.9%를 차지했습니다. 이 시장은 정밀 의학의 보급 확대, 유전체 및 분자진단 기술의 발전, 그리고 맞춤형 치료 결정을 가능하게 하는 바이오마커 기반 검사에 대한 수요 증가에 힘입어 견조한 성장을 이루고 있습니다.

또한, 동반진단의 활용 확대, 암 및 유전성 질환의 유병률 증가, 정밀 의료에 대한 투자 증가로 인해 예측 기간 동안 시장 성장이 더욱 가속화될 것으로 전망됩니다.

자주 묻는 질문

  • 맞춤형 진단 시장 규모는 어떻게 변화할 것으로 예상되나요?
  • 2025년 맞춤형 진단 시장에서 북미의 매출 점유율은 얼마인가요?
  • 맞춤형 진단 시장의 성장을 이끄는 주요 요인은 무엇인가요?
  • 동반진단의 활용 확대가 맞춤형 진단 시장에 미치는 영향은 무엇인가요?
  • 정밀 의료에 대한 투자가 맞춤형 진단 시장에 미치는 영향은 무엇인가요?

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 시장 : 변수, 동향, 범위

제4장 검사 유형별 비즈니스 분석

제5장 기술별 비즈니스 분석

제6장 용도별 비즈니스 분석

제7장 최종 용도별 비즈니스 분석

제8장 지역별 비즈니스 분석

제9장 경쟁 구도

KSM 26.09.29

Personalized Diagnostics Market Summary

The global personalized diagnostics market size was valued at USD 12.1 billion in 2025 and is projected to grow from USD 13.4 billion in 2026 to USD 30.0 billion by 2033, at a CAGR of 12.2% from 2026 to 2033. North America dominated the market with the largest revenue share of 39.9% in 2025. The market is witnessing robust growth due to the increasing adoption of precision medicine, advancements in genomic and molecular diagnostic technologies, and the rising demand for biomarker-based testing to enable personalized treatment decisions.

Furthermore, the expanding use of companion diagnostics, growing prevalence of cancer and genetic disorders, and increasing investments in precision healthcare are expected to further accelerate market growth during the forecast period.

Global Personalized Diagnostics Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global personalized diagnostics market report based on testing type, application, technology, end-use, and region:

  • Testing Type Scope Outlook (Revenue, USD Million, 2021 - 2033)
  • Genetic & Nutrigenomic Testing
  • Microbiome Testing
  • Metabolic Health Testing
  • Micronutrient & Deficiency Testing
  • Food Sensitivity & Intolerance Testing
  • Hormone Health Testing
  • Preventive Wellness & Longevity Testing
    • Epigenetic Age Testing
    • Telomere Length Analysis
    • Proteomics-based Aging Biomarkers
    • Others
  • Others
  • Technology Scope Outlook (Revenue, USD Million, 2021 - 2033)
  • Next-Generation Sequencing (NGS)
  • Immunoassays
  • Polymerase Chain Reaction (PCR)
  • Mass Spectrometry
  • Microarray Technology
  • Others
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Personalized Nutrition
  • Preventive Health Screening
  • Weight Management
  • Healthy Aging & Longevity
  • Chronic Disease Risk Assessment
  • Gut Health & Microbiome Analysis
  • Fitness & Lifestyle Optimization
  • Pharmacogenomics
  • Others
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Direct-to-Consumer (DTC)
  • Diagnostic Laboratories
  • Wellness & Nutrition Companies
  • Hospitals & Clinics
  • Others
  • Regional Scope Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • Thailand
    • South Korea
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Testing Type Segment
      • 1.1.1.2. Technology Segment
      • 1.1.1.3. Application Segment
      • 1.1.1.4. End Use Segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objective
    • 1.4.1. Objective 1
    • 1.4.2. Objective2
    • 1.4.3. Objective 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information or Data Analysis:
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Trends and Outlook
  • 3.4. Market Drivers
    • 3.4.1. Growing Adoption of Precision Medicine and Biomarker-Guided Therapies
    • 3.4.2. Advancements in Genomic Technologies and Next-Generation Sequencing (NGS)
    • 3.4.3. Rising Demand for Early Disease Detection and Personalized Healthcare Solutions
  • 3.5. Market Restraint Analysis
    • 3.5.1. Stringent regulatory guidelines
  • 3.6. Testing Type Analysis Tools
    • 3.6.1. Porter's Five Forces Analysis
    • 3.6.2. PESTEL Analysis

Chapter 4. Testing Type Business Analysis

  • 4.1. Genetic & Nutrigenomic Testing
    • 4.1.1. Genetic & Nutrigenomic Testing Market, 2021 - 2033 (USD Million)
  • 4.2. Microbiome Testing
    • 4.2.1. Microbiome Testing Market, 2021 - 2033 (USD Million)
  • 4.3. Metabolic Health Testing
    • 4.3.1. Metabolic Health Testing Market, 2021 - 2033 (USD Million)
  • 4.4. Micronutrient & Deficiency Testing
    • 4.4.1. Micronutrient & Deficiency Testing Market, 2021 - 2033 (USD Million)
  • 4.5. Food Sensitivity & Intolerance Testing
    • 4.5.1. Food Sensitivity & Intolerance Testing Market, 2021 - 2033 (USD Million)
  • 4.6. Hormone Health Testing
    • 4.6.1. Hormone Health Testing Market, 2021 - 2033 (USD Million)
  • 4.7. Preventive Wellness & Longevity Testing
    • 4.7.1. Preventive Wellness & Longevity Testing Market, 2021 - 2033 (USD Million)
      • 4.7.1.1. Preventive Wellness & Longevity Testing Market, 2021 - 2033 (USD Million)
    • 4.7.2. Epigenetic Age Testing
      • 4.7.2.1. Epigenetic Age Testing Market, 2021 - 2033 (USD Million)
    • 4.7.3. Telomere Length Analysis
      • 4.7.3.1. Telomere Length Analysis Market, 2021 - 2033 (USD Million)
    • 4.7.4. Proteomics-based Aging Biomarkers
      • 4.7.4.1. Proteomics-based Aging Biomarkers Market, 2021 - 2033 (USD Million)
    • 4.7.5. Others
      • 4.7.5.1. Others Market, 2021 - 2033 (USD Million)
  • 4.8. Others
    • 4.8.1. Others Market: Testing Type Movement Analysis

Chapter 5. Technology Business Analysis

  • 5.1. Personalized Diagnostics Market: Technology Movement Analysis
  • 5.2. Next-Generation Sequencing (NGS)
    • 5.2.1. Next-Generation Sequencing (NGS) Market, 2021 - 2033 (USD Million)
  • 5.3. Immunoassays
    • 5.3.1. Immunoassays Market, 2021 - 2033 (USD Million)
  • 5.4. Polymerase Chain Reaction (PCR)
    • 5.4.1. Polymerase Chain Reaction (PCR) Market, 2021 - 2033 (USD Million)
  • 5.5. Mass Spectrometry
    • 5.5.1. Mass Spectrometry Market, 2021 - 2033 (USD Million)
  • 5.6. Microarray Technology
    • 5.6.1. Microarray Technology Market, 2021 - 2033 (USD Million)
  • 5.7. Others
    • 5.7.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. Application Business Analysis

  • 6.1. Personalized Diagnostics Market: Application Movement Analysis
  • 6.2. Personalized Nutrition
    • 6.2.1. Microarray Technology Market, 2021 - 2033 (USD Million)
  • 6.3. Preventive Health Screening
    • 6.3.1. Microarray Technology Market, 2021 - 2033 (USD Million)
  • 6.4. Weight Management
    • 6.4.1. Microarray Technology Market, 2021 - 2033 (USD Million)
  • 6.5. Healthy Aging & Longevity
    • 6.5.1. Microarray Technology Market, 2021 - 2033 (USD Million)
  • 6.6. Chronic Disease Risk Assessment
    • 6.6.1. Microarray Technology Market, 2021 - 2033 (USD Million)
  • 6.7. Gut Health & Microbiome Analysis
    • 6.7.1. Microarray Technology Market, 2021 - 2033 (USD Million)
  • 6.8. Fitness & Lifestyle Optimization
    • 6.8.1. Microarray Technology Market, 2021 - 2033 (USD Million)
  • 6.9. Pharmacogenomics
    • 6.9.1. Microarray Technology Market, 2021 - 2033 (USD Million)

Chapter 7. End Use Business Analysis

  • 7.1. Personalized Diagnostics Market: End Use Movement Analysis
  • 7.2. Direct-to-Consumer (DTC)
    • 7.2.1. Direct-to-Consumer (DTC) Market, 2021 - 2033 (USD Million)
  • 7.3. Diagnostic Laboratories
    • 7.3.1. Diagnostic Laboratories Market, 2021 - 2033 (USD Million)
  • 7.4. Wellness & Nutrition Companies
    • 7.4.1. Wellness & Nutrition Companies Market, 2021 - 2033 (USD Million)
  • 7.5. Hospitals & Clinics
    • 7.5.1. Hospitals & Clinics Market, 2021 - 2033 (USD Million)
  • 7.6. Others
    • 7.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 8. Regional Business Analysis

  • 8.1. Personalized Diagnostics Market Share By Region, 2022 & 2033
  • 8.2. North America
    • 8.2.1. SWOT Analysis
    • 8.2.2. North America Personalized Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.2.3. U.S.
      • 8.2.3.1. Key Country Dynamics
      • 8.2.3.2. Competitive Scenario
      • 8.2.3.3. Regulatory Framework
      • 8.2.3.4. U.S. Personalized Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.2.4. Canada
      • 8.2.4.1. Key Country Dynamics
      • 8.2.4.2. Competitive Scenario
      • 8.2.4.3. Regulatory Framework
      • 8.2.4.4. Canada Personalized Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.2.5. Mexico
      • 8.2.5.1. Key Country Dynamics
      • 8.2.5.2. Competitive Scenario
      • 8.2.5.3. Regulatory Framework
      • 8.2.5.4. Mexico Personalized Diagnostics Market, 2021 - 2033 (USD Million)
  • 8.3. Europe
    • 8.3.1. SWOT Analysis
    • 8.3.2. Europe Personalized Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.3.3. UK
      • 8.3.3.1. Key Country Dynamics
      • 8.3.3.2. Competitive Scenario
      • 8.3.3.3. Regulatory Framework
      • 8.3.3.4. UK Personalized Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.3.4. Germany
      • 8.3.4.1. Key Country Dynamics
      • 8.3.4.2. Competitive Scenario
      • 8.3.4.3. Regulatory Framework
      • 8.3.4.4. Germany Personalized Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.3.5. France
      • 8.3.5.1. Key Country Dynamics
      • 8.3.5.2. Competitive Scenario
      • 8.3.5.3. Regulatory Framework
      • 8.3.5.4. France Personalized Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.3.6. Italy
      • 8.3.6.1. Key Country Dynamics
      • 8.3.6.2. Competitive Scenario
      • 8.3.6.3. Regulatory Framework
      • 8.3.6.4. Italy Personalized Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.3.7. Spain
      • 8.3.7.1. Key Country Dynamics
      • 8.3.7.2. Competitive Scenario
      • 8.3.7.3. Regulatory Framework
      • 8.3.7.4. Spain Personalized Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.3.8. Denmark
      • 8.3.8.1. Key Country Dynamics
      • 8.3.8.2. Competitive Scenario
      • 8.3.8.3. Regulatory Framework
      • 8.3.8.4. Denmark Personalized Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.3.9. Sweden
      • 8.3.9.1. Key Country Dynamics
      • 8.3.9.2. Competitive Scenario
      • 8.3.9.3. Regulatory Framework
      • 8.3.9.4. Sweden Personalized Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.3.10. Norway
      • 8.3.10.1. Key Country Dynamics
      • 8.3.10.2. Competitive Scenario
      • 8.3.10.3. Regulatory Framework
      • 8.3.10.4. Norway Personalized Diagnostics Market, 2021 - 2033 (USD Million)
  • 8.4. Asia Pacific
    • 8.4.1. SWOT Analysis
    • 8.4.2. Asia Pacific Personalized Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.4.3. Japan
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Competitive Scenario
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. Japan Personalized Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.4.4. China
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Competitive Scenario
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. China Personalized Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.4.5. India
      • 8.4.5.1. Key Country Dynamics
      • 8.4.5.2. Competitive Scenario
      • 8.4.5.3. Regulatory Framework
      • 8.4.5.4. India Personalized Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.4.6. Australia
      • 8.4.6.1. Key Country Dynamics
      • 8.4.6.2. Competitive Scenario
      • 8.4.6.3. Regulatory Framework
      • 8.4.6.4. Australia Personalized Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.4.7. Thailand
      • 8.4.7.1. Key Country Dynamics
      • 8.4.7.2. Competitive Scenario
      • 8.4.7.3. Regulatory Framework
      • 8.4.7.4. Thailand Personalized Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.4.8. South Korea
      • 8.4.8.1. Key Country Dynamics
      • 8.4.8.2. Competitive Scenario
      • 8.4.8.3. Regulatory Framework
      • 8.4.8.4. South Korea Personalized Diagnostics Market, 2021 - 2033 (USD Million)
  • 8.5. Latin America
    • 8.5.1. SWOT Analysis
    • 8.5.2. Latin America Personalized Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.5.3. Brazil
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Competitive Scenario
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. Brazil Personalized Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.5.4. Argentina
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Competitive Scenario
      • 8.5.4.3. Regulatory Framework
      • 8.5.4.4. Argentina Personalized Diagnostics Market, 2021 - 2033 (USD Million)
  • 8.6. MEA
    • 8.6.1. SWOT Analysis
    • 8.6.2. MEA Personalized Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.6.3. South Africa
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Competitive Scenario
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. South Africa Personalized Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.6.4. Saudi Arabia
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Competitive Scenario
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. Saudi Arabia Personalized Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.6.5. UAE
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Competitive Scenario
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. UAE Personalized Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.6.6. Kuwait
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Competitive Scenario
      • 8.6.6.3. Regulatory Framework
      • 8.6.6.4. Kuwait Personalized Diagnostics Market, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Company Categorization
  • 9.2. Strategy Mapping
  • 9.3. Company Market Share Analysis, 2025
  • 9.4. Company Profiles
  • 9.5. Thermo Fisher Scientific, Inc.
    • 9.5.1. Overview
    • 9.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.5.3. Testing Type Benchmarking
    • 9.5.4. Strategic Initiatives
  • 9.6. Illumina, Inc.
    • 9.6.1. Overview
    • 9.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.6.3. Testing Type Benchmarking
    • 9.6.4. Strategic Initiatives
  • 9.7. QIAGEN
    • 9.7.1. Overview
    • 9.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.7.3. Testing Type Benchmarking
    • 9.7.4. Strategic Initiatives
  • 9.8. F. Hoffmann-La Roche Ltd.
    • 9.8.1. Overview
    • 9.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.8.3. Testing Type Benchmarking
    • 9.8.4. Strategic Initiatives
  • 9.9. Bio-Rad Laboratories Inc.
    • 9.9.1. Overview
    • 9.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.9.3. Testing Type Benchmarking
    • 9.9.4. Strategic Initiatives
  • 9.10. Agilent Technologies
    • 9.10.1. Overview
    • 9.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.10.3. Testing Type Benchmarking
    • 9.10.4. Strategic Initiatives
  • 9.11. Exact Sciences Corporation
    • 9.11.1. Overview
    • 9.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.11.3. Testing Type Benchmarking
    • 9.11.4. Strategic Initiatives
  • 9.12. Guardant Health, Inc.
    • 9.12.1. Overview
    • 9.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.12.3. Testing Type Benchmarking
    • 9.12.4. Strategic Initiatives
  • 9.13. Danaher Corporation
    • 9.13.1. Overview
    • 9.13.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.13.3. Testing Type Benchmarking
    • 9.13.4. Strategic Initiatives
  • 9.14. Abbott
    • 9.14.1. Overview
    • 9.14.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.14.3. Testing Type Benchmarking
    • 9.14.4. Strategic Initiatives
×

원하시는 정보를 찾아 드릴까요?

보안문자 새로고침
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제
문의
원하시는 정보를
찾아 드릴까요?
문의주시면 필요한 정보를
신속하게 찾아드릴게요.
02-2025-2992
email
문의하기